Jefferies Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Predicting Strong Kyprolis Launch
Get Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Jefferies reiterates a 'Buy' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target of $101.00.
Analyst, Biren Amin, said, "With Kyprolis recently launched, we conducted a proprietary MM survey to address uncertainty typical around a biotech drug launch. Based on survey results there could be significant upside to our/St current ests and valuation. Our survey results predict a robust launch with stronger-than-expected 2013-14 uptake across key 2nd-line/beyond settings."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $67.80 yesterday.
Analyst, Biren Amin, said, "With Kyprolis recently launched, we conducted a proprietary MM survey to address uncertainty typical around a biotech drug launch. Based on survey results there could be significant upside to our/St current ests and valuation. Our survey results predict a robust launch with stronger-than-expected 2013-14 uptake across key 2nd-line/beyond settings."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $67.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
- Heineken NV (HEIA:NA) (HEINY) PT Raised to EUR77 at RBC Capital
- Atlas Copco AB (ATCOA:SS) (ATLKY) PT Raised to SEK150 at RBC Capital
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!